Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • Thursday
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-TermZacks Investment Research • Thursday
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?Zacks Investment Research • Wednesday
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty CompounderSeeking Alpha • 10/25/26
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 10/15/26
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026Accesswire • 09/02/26
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera TranscriptSeeking Alpha • 08/31/26
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia VeraAccesswire • 08/29/26
Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 AdvancementSeeking Alpha • 08/12/26
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026Zacks Investment Research • 08/11/26
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) StockZacks Investment Research • 08/07/26
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAccesswire • 08/05/26
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?Zacks Investment Research • 07/08/26
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26